WNY Asset Management LLC Sells 14,446 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

WNY Asset Management LLC reduced its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 42.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 19,465 shares of the biopharmaceutical company's stock after selling 14,446 shares during the period. WNY Asset Management LLC's holdings in Gilead Sciences were worth $1,798,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the business. Bridgewater Associates LP increased its stake in Gilead Sciences by 122.7% in the fourth quarter. Bridgewater Associates LP now owns 460,936 shares of the biopharmaceutical company's stock valued at $42,577,000 after purchasing an additional 253,994 shares in the last quarter. McAdam LLC increased its position in shares of Gilead Sciences by 16.7% during the fourth quarter. McAdam LLC now owns 25,372 shares of the biopharmaceutical company's stock worth $2,344,000 after acquiring an additional 3,627 shares in the last quarter. Nissay Asset Management Corp Japan ADV increased its position in shares of Gilead Sciences by 5.2% during the fourth quarter. Nissay Asset Management Corp Japan ADV now owns 284,243 shares of the biopharmaceutical company's stock worth $26,750,000 after acquiring an additional 14,009 shares in the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management increased its position in shares of Gilead Sciences by 3.9% during the fourth quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 142,167 shares of the biopharmaceutical company's stock worth $13,132,000 after acquiring an additional 5,382 shares in the last quarter. Finally, Foster & Motley Inc. increased its position in shares of Gilead Sciences by 80.4% during the fourth quarter. Foster & Motley Inc. now owns 10,587 shares of the biopharmaceutical company's stock worth $978,000 after acquiring an additional 4,718 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on GILD shares. Cantor Fitzgerald started coverage on shares of Gilead Sciences in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 price objective for the company. Needham & Company LLC reissued a "hold" rating on shares of Gilead Sciences in a research report on Wednesday, May 21st. BMO Capital Markets increased their price objective on shares of Gilead Sciences from $110.00 to $115.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 12th. Royal Bank of Canada increased their target price on shares of Gilead Sciences from $84.00 to $90.00 and gave the stock a "sector perform" rating in a report on Wednesday, February 12th. Finally, Bank of America increased their target price on shares of Gilead Sciences from $116.00 to $126.00 and gave the stock a "buy" rating in a report on Wednesday, March 5th. Nine equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $110.55.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD traded down $0.65 during mid-day trading on Wednesday, reaching $108.44. 4,591,543 shares of the company were exchanged, compared to its average volume of 7,722,873. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $119.96. The stock has a market capitalization of $134.89 billion, a P/E ratio of 293.08, a P/E/G ratio of 0.71 and a beta of 0.26. The company's 50-day simple moving average is $105.33 and its 200-day simple moving average is $100.52. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The business had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. During the same period last year, the firm earned ($1.32) earnings per share. Gilead Sciences's revenue for the quarter was down .3% compared to the same quarter last year. As a group, research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be given a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.91%. The ex-dividend date of this dividend is Friday, June 13th. Gilead Sciences's dividend payout ratio is 66.53%.

Insider Buying and Selling

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the firm's stock in a transaction dated Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total value of $3,010,560.00. Following the transaction, the insider now directly owns 121,152 shares of the company's stock, valued at $13,026,263.04. This trade represents a 18.77% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Andrew D. Dickinson sold 17,929 shares of the firm's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $118.17, for a total transaction of $2,118,669.93. Following the completion of the transaction, the chief financial officer now directly owns 169,061 shares in the company, valued at approximately $19,977,938.37. This represents a 9.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 50,929 shares of company stock valued at $5,644,780. 0.27% of the stock is owned by company insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.